New progress of gallstone formation mechanism after weight loss

doi:10.3877/cma.j.issn.1674-3946.2024.01.026

Abstract

Abstract:

Obesity affects people's respiratory, circulation, endocrine, reproductive and other systems, and is closely related to diabetes, hypertension, hyperlipidemia and other diseases. In order to solve the problem of obesity, improving living habits, taking anti-obesity drugs and weight loss surgery are the three most common ways. Among them, bariatric surgery can be considered an effective treatment to address obesity and its obesity-related comorbidities. At present, the commonly used types of weight loss surgery include laparoscopic adjustable gastric banding, sleeve gastrectomy, large gastric bending and folding, and gastric bypass. With the development of bariatric surgery, long-term complications after bariatric surgery have gradually emerged. As one of the common complications of bariatric surgery, gallstone after bariatric surgery has attracted extensive attention from scholars because it can further induce acute cholecystitis, cholangitis and biliary pancreatitis. By searching relevant literature, this paper summarizes and analyzes the current research status and existing problems of domestic and foreign scholars on the formation of gallstones after weight loss, aiming to provide reference for further exploring the molecular mechanism of the formation of gallstones after weight loss and searching for targeted prevention and treatment measures.

Key words: Obesity, Bariatric Surgery, Gallstones

Kailun Ji, Shaolong Hao, Haitao Sun, Wei Han. New progress of gallstone formation mechanism after weight loss[J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2024, 18(01): 100-103.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhpwkssxzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-3946.2024.01.026

https://zhpwkssxzz.cma-cmc.com.cn/EN/Y2024/V18/I01/100

References 38

[3]	韩莹,齐向秀,刘丽娜. Roux-en-Y胃旁路术与袖状胃切除术治疗反复肥胖型急性高脂血症性胰腺炎的临床比较[J/CD].中华普外科手术学杂志（电子版）, 2021, 15(03): 347–350.
[4]	买买提·依斯热依力,阿巴伯克力·乌斯曼,艾克拜尔·艾力等.腹腔镜袖状胃切除术治疗肥胖合并2型糖尿病的临床研究[J/CD].中华普外科手术学杂志（电子版）, 2021, 15(05): 497–500.
[5]	Liakopoulos V，Franzén S，Svensson AM，et al. Pros and cons of gastric bypass surgery in individuals with obesity and type 2 diabetes: nationwide，matched，observational cohort study[J]. BMJ Open, 2019, 9(1): e023882.
[6]	Sneineh MA，Harel L，Elnasasra A，et al. Increased incidence of symptomatic cholelithiasis after bariatric roux-en-y gastric bypass and previous bariatric surgery: a single center experience[J]. Obesity Surgery, 2020, 30(3): 846–850.
[7]	Talha A，Abdelbaki T，Farouk A，et al. Cholelithiasis after bariatric surgery，incidence，and prophylaxis: randomized controlled trial[J]. Surgical Endoscopy, 2019, 34(12): 5331–5337.
[8]	Yuan S，Gill D，Giovannucci EL，et al. Obesity，type 2 diabetes，lifestyle factors，and risk of gallstone disease: a mendelian randomization investigation[J]. Clinical Gastroenterology and Hepatology, 2022, 20(3): e529–e537.
[9]	Altieri MS，Yang J，Nie L，et al. Incidence of cholecystectomy after bariatric surgery[J]. Surgery for Obesity and Related Diseases, 2018, 14(7): 992–996.
[10]	Alsaif F，Alabdullatif F，Aldegaither M，et al. Incidence of symptomatic cholelithiasis after laparoscopic sleeve gastrectomy and its association with rapid weight loss[J]. Saudi Journal of Gastroenterology, 2020, 26(2): 94–98.
[11]	Verhoeff K，Mocanu V，Dang J，et al. Characterization and risk factors for early biliary complications following elective bariatric surgery: an mbsaqip analysis[J]. Obesity Surgery, 2022, 32(4): 1170–1177.
[12]	Tsirline VB，Keilani ZM，El Djouzi S，et al. How frequently and when do patients undergo cholecystectomy after bariatric surgery？[J]. Surgery for Obesity and Related Diseases, 2014, 10(2): 313–321.
[13]	Guzmán HM，Sepúlveda M，Rosso N，et al. Incidence and risk factors for cholelithiasis after bariatric surgery[J]. Obesity Surgery, 2019, 29(7): 2110–2114.
[14]	Alimoğulları M，Buluş H. Predictive factors of gallstone formation after sleeve gastrectomy: a multivariate analysis of risk factors[J]. Surgery Today, 2020, 50(9): 1002–1007.
[15]	Hashimoto K，Nagao Y，Nambara S，et al. Association between anti-helicobacter pylori antibody seropositive and de novo gallstone formation after laparoscopic sleeve gastrectomy for japanese patients with severe obesity[J]. Obesity Surgery, 2022, 32(10): 3404–3409.
[16]	Di Ciaula A，Wang D Q-H，Portincasa P. An update on the pathogenesis of cholesterol gallstone disease[J]. Current Opinion in Gastroenterology, 2018, 34(2): 71–80.
[17]	Krawczyk M，Lütjohann D，Schirin-Sokhan R，et al. Phytosterol and cholesterol precursor levels indicate increased cholesterol excretion and biosynthesis in gallstone disease[J]. Hepatology, 2012, 55(5): 1507–1517.
[18]	Benetti A，Del Puppo M，Crosignani A，et al. Cholesterol metabolism after bariatric surgery in grade 3 obesity: differences between malabsorptive and restrictive procedures[J]. Diabetes Care, 2012, 36(6): 1443–1447.
[19]	Ji Y，Lee H，Kaura S，et al. Effect of bariatric surgery on metabolic diseases and underlying mechanisms[J]. Biomolecules, 2021, 11(11): 1582.
[20]	Akalestou E，Miras AD，Rutter GA，et al. Mechanisms of weight loss after obesity surgery[J]. Endocrine Reviews, 2021, 43(1): 19–34.
[21]	Yoo KS，Choi HS，Jun DW，et al. MUC expression in gallbladder epithelial tissues in cholesterol-associated gallbladder disease[J]. Gut and Liver, 2016, 10(5): 851–858.
[1]	Pan XF，Wang L，Pan A. Epidemiology and determinants of obesity in china[J]. Lancet Diabetes Endocrinol, 2021, 9(6): 373–392.
[2]	Lin X，Li H. Obesity: epidemiology，pathophysiology，and therapeutics[J]. Frontiers in Endocrinology, 2021, 12: 706978.
[22]	Wang HH，Afdhal NH，Gendler SJ，et al. Evidence that gallbladder epithelial mucin enhances cholesterol cholelithogenesis in muc1 transgenic mice[J]. Gastroenterology, 2006, 131(1): 210–222.
[23]	Gustafsson U，Benthin L，Granström L，et al. Changes in gallbladder bile composition and crystal detection time in morbidly obese subjects after bariatric surgery[J]. Hepatology, 2005, 41(6): 1322–1328.
[24]	Lavoie B，Nausch B，Zane EA，et al. Disruption of gallbladder smooth muscle function is an early feature in the development of cholesterol gallstone disease[J]. Neurogastroenterology &Motility, 2012, 24(7): e313–e324.
[25]	Al-Jiffry BO，Shaffer EA，Saccone GT，et al. Changes in gallbladder motility and gallstone formation following laparoscopic gastric banding for morbid obesity[J]. Canadian Journal of Gastroenterology, 2003, 17(3): 169–174.
[26]	Gether IM，Nexøe-Larsen C，Knop FK. New avenues in the regulation of gallbladder motility—implications for the use of glucagon-like peptide–derived drugs[J]. The Journal of Clinical Endocrinology &Metabolism, 2018, 104(7): 2463–2472.
[27]	Hu H，Shao W，Liu Q，et al. Gut microbiota promotes cholesterol gallstone formation by modulating bile acid composition and biliary cholesterol secretion[J]. Nature Communications, 2022, 13(1): 252.
[28]	Chaudhari SN，Luo JN，Harris DA，et al. A microbial metabolite remodels the gut-liver axis following bariatric surgery[J]. Cell Host &Microbe, 2021, 29(3): 408–424.e7.
[29]	Wang Q，Jiao L，He C，et al. Alteration of gut microbiota in association with cholesterol gallstone formation in mice[J]. BMC Gastroenterology, 2017, 17(1): 74.
[30]	Jahansouz C，Staley C，Bernlohr D A，et al. Sleeve gastrectomy drives persistent shifts in the gut microbiome[J]. Surgery for Obesity and Related Diseases, 2017, 13(6): 916–924.
[31]	Ribeiro-Parenti L，Jarry AC，Cavin JB，et al. Bariatric surgery induces a new gastric mucosa phenotype with increased functional glucagon-like peptide-1 expressing cells[J]. Nature Communications, 2021, 12(1): 110.
[32]	Zhang Z，Du Z，Liu Q，et al. Glucagon-like peptide 1 analogue prevents cholesterol gallstone formation by modulating intestinal farnesoid x receptor activity[J]. Metabolism, 2021, 118: 154728.
[33]	Albaugh VL，Banan B，Antoun J，et al. Role of Bile Acids and GLP-1 in Mediating the Metabolic Improvements of Bariatric Surgery[J].Gastroenterology, 2019, 156(4): 1041–1051.e4.
[34]	Cunningham RM，Jones KT，Kuhn JE，et al. Asymptomatic cholelithiasis and bariatric surgery: a comprehensive long-term analysis of the risks of biliary disease in patients undergoing primary roux-en-y gastric bypass[J]. Obesity Surgery, 2020, 31(3): 1249–1255.
[35]	Şen O，Türkçapar AG. Risk of asymptomatic gallstones becoming symptomatic after laparoscopic sleeve gastrectomy[J]. The American Surgeon, 2023, 89(1): 69–71.
[36]	Della Penna A，Lange J，Hilbert J，et al. Ursodeoxycholic acid for 6 months after bariatric surgery is impacting gallstone associated morbidity in patients with preoperative asymptomatic gallstones[J]. Obesity Surgery, 2019, 29(4): 1216–1221.
[37]	Haal S，Guman MSS，De Brauw LM，et al. Cost-effectiveness of ursodeoxycholic acid in preventing new-onset symptomatic gallstone disease after Roux-en-Y gastric bypass surgery[J]. British Journal of Surgery, 2022, 109(11): 1116–1123.
[38]	Cao C，Shao YK，Yao QY. Role and change of the gut microbiota after bariatric surgery[J]. Chinese journal of gastrointestinal surgery, 2022, 25(7): 648–653.

Please choose a citation manager

Content to export